Climb Bio to Engage Investors at Key Conferences
Climb Bio, Inc., a clinical-stage biotechnology company committed to developing therapeutics for immune-mediated diseases, is excited to announce participation in several high-profile investor conferences in 2025. The company's dedicated executive team is set to engage with potential investors, showcasing its innovative projects and therapeutic advancements.
Conferences Schedule
Cantor Global Healthcare Conference
The Cantor Global Healthcare Conference provides a platform for leading healthcare companies to discuss their developments. Climb Bio will be conducting a fireside chat along with one-on-one meetings, allowing investors to gain deeper insights into its operations. The meeting is scheduled for Friday, September 5, 2025, at 10:55 a.m. ET.
Baird Global Healthcare Conference
Shortly thereafter, Climb Bio will participate in the Baird Global Healthcare Conference on Tuesday, September 9, 2025, at 4:20 PM ET. This event will also feature a fireside chat and opportunities for personal meetings, furthering discussions on Climb Bio's innovative therapeutic pipeline.
Morgan Stanley Annual Global Healthcare Conference
The following day, the team continues its investor relations efforts at the Morgan Stanley Annual Global Healthcare Conference on September 10, 2025. This event will center exclusively around one-on-one meetings, providing intimate conversations about Climb Bio’s advancements and future endeavors.
Stifel Virtual Immunology and Inflammation Forum
In an effort to reach broader audiences, Climb Bio will also host a presentation at the Stifel Virtual Immunology and Inflammation Forum on September 16, 2025, at 10:30 a.m. ET. This virtual event will incorporate both a presentation and one-on-one investor meetings.
About Climb Bio, Inc.
Climb Bio, Inc. is at the forefront of biopharmaceutical development, focusing on therapeutics targeted at immune-mediated diseases. Among its promising pipeline is budoprutug, an anti-CD19 monoclonal antibody with shown efficacy in B-cell depletion, potentially benefitting a wide array of B-cell mediated diseases. Another key product, CLYM116, is an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. The ongoing advancements in these treatments are aimed at improving the quality of life for patients impacted by such diseases.
Investor and Media Contacts
For any inquiries, please reach out to Carlo Tanzi, Ph.D., from Kendall Investor Relations via the email: catanzi@kendallir.com. Climb Bio's commitment to transparency with investors ensures that all questions and discussions are adequately addressed during these upcoming events.
Frequently Asked Questions
What is the purpose of Climb Bio's participation in these conferences?
Climb Bio aims to provide insights into its business and therapeutic pipeline, engage with potential investors, and strengthen relationships with current stakeholders.
When is the Cantor Global Healthcare Conference happening?
The Cantor Global Healthcare Conference is scheduled for September 5, 2025.
How many conferences is Climb Bio participating in?
Climb Bio is participating in four major conferences throughout September 2025.
What developments will Climb Bio highlight during the events?
Climb Bio will showcase its lead therapeutic candidates, including budoprutug and CLYM116, focusing on their efficacy and the potential benefits for patients.
Who can investors contact for more information?
Investors can contact Carlo Tanzi at catanzi@kendallir.com for further inquiries about the conferences and Climb Bio's programs.
